Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
03/04/2024 13:18
April 3 (Reuters) - BetterLife Pharma Inc BETR.CD :
* BETTERLIFE ANNOUNCES CLOSING OF $1.168 MILLION CONVERTIBLE
DEBENTURES TO FURTHER ADVANCE IND-ENABLING STUDIES OF ITS
NON-HALLUCINOGENIC LSD-BASED DRUG CANDIDATE BETR-001
Source text for Eikon: ID:nGNX9Kg3XY
Further company coverage: BETR.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BetterLife Pharma
See all newsBrief: Betterlife Pharma Provides Scientific Update On Neuroplastogenic Activity Of BETR-001
Brief: Betterlife Pharma Advanced In IND-enabling Studies For BETR-001
Brief: BetterLife Announces Closing Of $1.168 Million Convertible Debentures To Further Advance IND-Enabling Studies Of Its Non-Hallucinogenic LSD-Based Drug Candidate BETR-001
Brief: Omineca Announces $2 Mln Brokered Financing Of Flow-Through Units
Brief: Betterlife Announces Pricing Of Proposed Offering Of Units